Quarterly report pursuant to Section 13 or 15(d)

Business Acquisition

Business Acquisition
9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Business Acquisition

Note 4 – Business Acquisition


On January 8, 2019, MedoveX completed its business combination with RMS under which MedoveX purchased certain assets and assumed certain liabilities of RMS, otherwise referred to as the Merger. Pursuant to the terms of the APA, MedoveX issued to the shareholders of RMS 33,661 shares plus 6,111 additional Exchange Shares (based on closing the sale of $2,000,000 of new securities) for a total of 39,772 shares of Series C Preferred Stock where each share of Series C Preferred stock automatically converted into 1,000 shares of common stock and represent approximately 55% of the outstanding voting shares of the Company.


Under the terms of the APA, the Company issued additional “Exchange Shares” to the shareholders of RMS to maintain the 55% ownership and not be diluted by the sale of convertible securities (“New Shares Sold”) until MedoveX raised an additional $5,650,000 via the issuance of new securities. On the date of closing the Company issued 6,111 additional Exchange Shares to RMS Shareholders as a result of the issuance of additional securities, which are included in the 39,772 shares above. Subsequent to the closing of the purchase transaction, an incremental 11,153 additional Exchange Shares were issued, for a total of 17,264 additional Exchange Shares. All additional Exchange Shares have been issued to the shareholders of RMS and these Series C Preferred shares converted to 17,263,889 shares of common stock; no additional equity will be issued to RMS.


Because RMS shareholders owned approximately 55% of the voting stock of MedoveX after the transaction, RMS was deemed to be the acquiring company for accounting purposes (the “Acquirer”) and the transaction is accounted for as a reverse acquisition under the acquisition method of accounting for business combinations in accordance with U.S. GAAP. The assets acquired and the liabilities assumed of RMS included as part of the purchase transaction are recorded at historical cost. Accordingly, the assets and liabilities of MedoveX (the “Acquiree”) are recorded as of the Merger closing date at their estimated fair values.


Purchase Price Allocation


The purchase price for the acquisition of the Acquiree has been allocated to the assets acquired and liabilities assumed based on their estimated fair values.


The acquisition-date fair value of the consideration transferred is as follows:


Common shares issued and outstanding     24,717,270  
Common shares reserved for issuance upon conversion of the outstanding Series B Preferred Stock     2,312,500  
Total Common shares     27,029,770  
Closing price per share of MedoveX Common stock on January 8, 2019   $ 0.40  
Fair value of outstanding warrants and options     2,220,000  
Cash consideration to RMS     (350,000 )
Total consideration   $ 12,681,908  


Prior to the transaction, MedoveX had 24,500,000 shares of common stock outstanding at a market capitalization of $9,800,000. The estimated fair value of the net assets of MedoveX was $8,400,000 as of January 8, 2019. Measuring the fair value of the net assets to be received by RMS was readily determinable based upon the underlying nature of the net assets. The fair value of the MedoveX common stock was above the fair value of its net assets. The MedoveX net asset value was primarily comprised of definite-lived intangibles as of the closing and the RMS interest in the merger is significantly related to obtaining access to the public market. Therefore, the fair value of the MedoveX stock price and market capitalization as of the closing date is considered to be the best indicator of the fair value and, therefore, the purchase price consideration.


The following table summarizes the fair values of the assets acquired and liabilities assumed at the date of acquisition on January 8, 2019:


Cash   $ (302,710 )
Accounts receivable     145,757  
Inventory     131,455  
Prepaid expenses     46,153  
Property and equipment     30,393  
Other     2,751  
Intangibles     3,680,000  
Goodwill     12,564,401  
Total assets acquired   $ 16,298,200  
Accounts payable and other accrued liabilities     1,645,399  
Derivative liability     1,215,677  
Interest-bearing liabilities and other     755,216  
Net assets acquired   $ 12,681,908  


Intangible assets are recorded as definite-lived assets and amortized over the estimated period of economic benefit. Intangible assets represent the fair value of patents and related proprietary technology for the DenerveX System. During the fourth quarter of 2019 the Company recorded an impairment charge of $2,944,000 related to the carrying value of its intangible assets.


Goodwill is calculated as the difference between the acquisition-date fair value of the consideration transferred and the fair values of the assets acquired, and liabilities assumed. Goodwill is not expected to be deductible for income tax purposes. Goodwill is recorded as an indefinite-lived asset and is not amortized but tested for impairment on an annual basis or when indications of impairment exist. During the fourth quarter of 2019 the Company recorded an impairment charge of approximately $12,564,000 related to the carrying value of goodwill.


The derivative liability relates to the liability associated with warrants issued with the securities purchase agreements executed in May 2018, which liability was assumed in the Merger (see Note 12).


Total interest-bearing liabilities and other liabilities assumed are as follows:


Notes payable   $ 99,017  
Short-term convertible notes payable     598,119  
Dividend payable     57,813  
Deferred rent     267  
Total interest-bearing and other liabilities   $ 755,216  


For further discussion of the notes payable and short-term convertible notes payable, refer to Note 11- “Short-term Debt” to these interim financial statements.